NCT04244396 - Persistent Atrial Fibrillation (AF) APAC (Asia Pacific) Observational Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions

Persistent Atrial Fibrillation

Interventions

DEVICE

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)

TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.

Trial Locations (9)

Unknown

Prince of Wales Hospital, Hong Kong

National Heart Centre Singapore, Singapore

National University Hospital, Singapore

Sejong Hospital, Bucheon-si

Severance Hospital, Yonsei University Health System, Seoul

Asan Medical Centre, Soeul

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

Taipei Veterans General Hospital, Taipei

Phramongkutklao Hospital, Bangkok